Key Highlights

  • Novavax sank after the WHO assessed the risk from a reported pneumonic plague outbreak as low.
  • The move reversed a burst of interest from the previous evening, when Novavax, Moderna and Vaxcyte were trending on outbreak reports.
  • Moderna closed at $187.46, and rejoins the Nasdaq-100 on October 9.
  • Vaxcyte traded lower before the open after launching a $1 billion Capital raise following its own Vaccine data win.

Novavax (NASDAQ:NVAX) sank on Tuesday, October 6, ranking among the most-discussed decliners in the Russell 2000. The selling followed the World Health Organization's assessment that the risk from a pneumonic plague outbreak was low, according to live market coverage.

The move reversed a burst of interest from the previous evening. On Monday after hours, Novavax, Moderna (NASDAQ:MRNA) and Vaxcyte (NASDAQ:PCVX) were trending on reports of suspected pneumonic plague cases in Russia. Traders often bid up vaccine and infectious-disease stocks quickly on outbreak headlines, and those gains can fade just as fast when health authorities signal that the threat is contained.

Novavax is a vaccine developer. The earlier enthusiasm appeared to reflect a broad bet on outbreak-related Demand across vaccine makers, which helps explain why traders moved quickly once the WHO's guidance eased concern.

Moderna and Peers Followed

Novavax was not alone. Moderna closed at $187.46 after sliding, with the decline attributed to profit-taking after its plague-related gains. Moderna rejoins the Nasdaq-100 on October 9. Vaxcyte also traded lower before the open after launching $500 million of common stock and pre-funded warrants plus $500 million of convertible notes, following a jump on Monday on Phase 3 data for its pneumococcal vaccine candidate VAX-31. Its prospectus said VAX-31 "met all prespecified co-primary immunogenicity endpoints in adults 50 and older."

Health Care Was Tuesday's Lone Loser

The vaccine retreat fed into a broader slump for health care, which was the only one of the 11 major S&P 500 sectors to close lower. Illumina (NASDAQ:ILMN), Danaher (NYSE:DHR), Thermo Fisher (NYSE:TMO) and other tools and diagnostics names slid, and small-cap biotech fared even worse. Only 48 of the 428 health-care stocks in the Russell 2000 rose on the day.

The wider market was buoyant. The S&P 500 gained about 45 points to a record 7,818.93, the Nasdaq Composite closed at a record just under 27,600, and the Dow added 253 points to 51,521.28. Small caps did not share in the gains: the Russell 2000 fell around 17 points to roughly 2,830.

Rates and the Risk Backdrop

The 10-year Treasury Yield eased to about 5.28, giving some relief after touching 5.33 on October 1, its highest since 2002. Even so, borrowing costs remain elevated for companies that depend on outside funding. The Federal Reserve lifted its target range to 3.75 to 4.00 in September, and futures suggest a strong majority of traders expect it to hold at the October 27-28 meeting.

Health Agency Updates Will Shape the Next Move

For Novavax and its peers, the next leg depends heavily on public-health news flow. Any update from the WHO or national health agencies on the reported outbreak in Russia could quickly revive or further cool the theme. Moderna's return to the Nasdaq-100 on October 9 and how Vaxcyte's share sale settles may also shape sentiment across vaccine stocks.